Figure 7.
![Monitoring of molecular and cytogenetic alterations in 7 patients with MDS. Five patients receiving treatment (3 azacitidine, 1 FLAG-IDA+HCT, and 1 HIF [hypoxia-inducible factor inhibitor]) and 2 untreated cases were included. BM VAF dynamics are shown with dotted lines and cfDNA dynamics are shown with solid lines. CMML, chronic myelomonocytic leukemia; CNA, copy number alteration; HCT, hematopoietic cell transplantation; ND, not detected.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/6/10/10.1182_bloodadvances.2021006565/3/advancesadv2021006565f7.png?Expires=1735485167&Signature=2549okZHsFp--LftV9rBNRk6dYJjO5kSrFryJoK3EqxB9TE7d3~oObFKFSM18eTRJFDNl0FGWy310Q3vT6FfikN68RDaETAct04HW1-NmNKZ5tejggvlXm6DktQPiuYLlCUJ4T3WD4OptGU3hQy3k~bpDx41WAndf3IMLQttYS7V6pef24jFLGDrStjGBK5GZA82nS5PTJ4tu5SfQNtuzjTngWGezLybrc3Gu4tyRBAZNtdv-wWsITIAsphyXGmSQMmOf0g01oVwvOgbUer6Dm-5VdCya4m3VvWkwSvxu5MW6dN7F7V-p~GsZJuhuzVHFkAq96P3L-TfO79qu4RGgQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Monitoring of molecular and cytogenetic alterations in 7 patients with MDS. Five patients receiving treatment (3 azacitidine, 1 FLAG-IDA+HCT, and 1 HIF [hypoxia-inducible factor inhibitor]) and 2 untreated cases were included. BM VAF dynamics are shown with dotted lines and cfDNA dynamics are shown with solid lines. CMML, chronic myelomonocytic leukemia; CNA, copy number alteration; HCT, hematopoietic cell transplantation; ND, not detected.